VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced that William T. Lowrance, MD, MPH, MBA will serve as the company’s Chief Medical Officer. Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.
“We are privileged to welcome Dr. Lowrance to Vesica Health. His expertise in urology and extensive experience in conducting clinical trials, as well as his deep understanding of the challenges associated with urologic malignancies, make him an invaluable addition to our team,” commented Christopher Thibodeau, CEO of Vesica Health. Thibodeau emphasized that ~ 20,000 bladder cancer cases are missed every year under the current standard of care, leading to more advanced disease and higher mortality rates, and that patients deserve better. “Dr. Lowrance will play a vital role in shaping our clinical strategy, creating a strong patient-centric organization, and contributing to our mission of transforming the management of hematuria patients and improving the early detection of bladder cancer,” he continued.
“I have devoted my career to researching and treating urologic cancers, striving to improve patient care and ultimately, survival,” said Dr. William T. Lowrance, Chief Medical Officer of Vesica Health. “I am truly honored to join the management team at Vesica and contribute to our shared mission of supporting those battling bladder cancer. We are at a pivotal moment with the advent of well-validated genomic tests like AssureDx, which hold the promise of fundamentally changing the diagnosis and management of bladder cancer. By identifying patients at an increased risk of developing the disease at an early stage, when treatment is most effective, we can offer hope and support to those in need.”
Dr. Lowrance is an attending urologic oncologist at Bon Secours Mercy Health, specializing in the treatment of urologic malignancies, with a focus on bladder cancer. Formerly, he served as Associate Professor of Urology and the leader of the Genitourinary Disease Center at Huntsman Cancer Institute at the University of Utah, and previously as an Adjunct Faculty Instructor of Surgery, at Memorial Sloan-Kettering Cancer Center in New York. Dr. Lowrance earned his Master of Business Administration from the David Eccles School of Business at the University of Utah, a Master of Public Health from Harvard School of Public Health, a Medical Degree from the Medical University of South Carolina, and a BA in Chemistry from Washington and Lee University. He performed his urology residency at Vanderbilt University Medical Center and his Fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center. Dr. Lowrance’s research focuses on understanding and improving patient clinical outcomes and has published numerous peer-reviewed urologic articles, book chapters, and editorials.
While serving as the Chief Medical Officer of Vesica Health, Dr. Lowrance will continue his medical practice at Bon Secours Mercy Health. He is the chair of the American Urological Association’s Advanced Prostate Cancer Clinical Guidelines committee and has served on the editorial board for multiple medical journals. He peer reviews medical manuscripts for a variety of medical journals.
